T. Rowe Price Associates
APRE icon

T. Rowe Price Associates’s Aprea Therapeutics APRE Stock Holding History

T. Rowe Price Associates’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,494
Closed -$147K – 2844
2020
Q4 		$147K Sell
1,494
-13,714
-90% -$6.52M ﹤0.01% 2589
2020
Q3 		$7.32M Sell
15,208
-532
-3% -$298K ﹤0.01% 1358
2020
Q2 		$12.2M Buy
+15,740
New +$10.3M ﹤0.01% 1254

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

T. Rowe Price Associates's APRE Position: Q1 2021 in Review

T. Rowe Price Associates sold out of Aprea Therapeutics (APRE) in Q1 2021, closing a stake of 1,494 shares — an estimated $147K sold.

T. Rowe Price Associates first reported a position in APRE in Q2 2020 and held it in 3 quarters. The position peaked at $12.2M in Q2 2020. 67 funds tracked by Wall St. Rank hold APRE as of Q1 2021.

  • T. Rowe Price Associates reported no remaining Aprea Therapeutics position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,494 Aprea Therapeutics shares in Q1 2021, an estimated $147K.
  • T. Rowe Price Associates first reported a position in Aprea Therapeutics in Q2 2020 and held it in 3 quarters.
  • T. Rowe Price Associates's Aprea Therapeutics position peaked at $12.2M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.